LivaNova LIVN · NASDAQ
$78.14 +0.72% (+$0.56)
Summary
67 / 100 · Bulios Score
What speaks for it
- It earns 18 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $516.6M against $351.9M.
- Out of every 100 USD of revenue, 13 USD is left as net profit.
- Revenue grew by 11% a year over the last 3 years.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 22.8 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 8.2% a year over 5 years. Over the last 3 years it grew by 11% a year. For the next fiscal year analysts expect revenue to grow by 9.8%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 32 USD
- Research and development 14 USD
- Sales and administration 41 USD
- Taxes and other 0.7 USD
- Net profit 13 USD
Net profit, industry median (Medical - Devices) 6.9 USD
Out of every 100 USD of revenue, 13 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.4 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 11
- Hold 3
- Sell 1
Today's price within the analysts' price targets
The average target of $88.5 is 13% above today's price. 73% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Cardiopulmonary Segment 57%
- Neuromodulation Segment 43%
By region
- UNITED STATES 53%
- Locations Excluding The United States And Europe 27%
- Europe 19%
Cardiopulmonary Segment brings in 57% of revenue.
Segments in detail